Business News

BioPharmX presents early research results of hydrophilic topical gel for acne treatment

BioPharmX Corp. has announced that it will be presenting data on its investigational drug, BPX-01, at the Skin Disease Education Foundation’s 11th Annual Women’s & Pediatric Dermatology Seminar, according to a press release.

BPX-01 is a hydrophilic topical gel designed to deliver antibiotic into the skin’s target anatomy where acne develops, according to the release. The data being presented include the gel’s efficacy in reaching the sebaceous glands compared with current lipophilic ointments, which can occlude pores and often compensates the limited penetration into the skin by significantly increasing drug dosage, the release stated.

“Our studies indicate that BPX-01 is more effective at delivering antibiotic into the skin than drug in a lipophilic formulation, suggesting that lower doses of antibiotic can provide superior efficacy over other formulations with higher doses,” Kin F. Chan, PhD, executive vice president of research and development at BioPharmX Corporation, said in the release. “Usability studies indicate that BPX-01 distributes evenly, is not sticky and does not occlude or irritate the skin, indicating that it could offer a significant advancement in the treatment of acne.”

According to the release the American Academy of Dermatology, acne is the “most common skin condition in the United States,” affecting 40 to 50 million Americans at any given moment and can lead to permanent scarring, low self-esteem, depression and anxiety.

The dermatology seminar will be held in Newport Beach, California, Oct. 23-24.

BioPharmX Corp. has announced that it will be presenting data on its investigational drug, BPX-01, at the Skin Disease Education Foundation’s 11th Annual Women’s & Pediatric Dermatology Seminar, according to a press release.

BPX-01 is a hydrophilic topical gel designed to deliver antibiotic into the skin’s target anatomy where acne develops, according to the release. The data being presented include the gel’s efficacy in reaching the sebaceous glands compared with current lipophilic ointments, which can occlude pores and often compensates the limited penetration into the skin by significantly increasing drug dosage, the release stated.

“Our studies indicate that BPX-01 is more effective at delivering antibiotic into the skin than drug in a lipophilic formulation, suggesting that lower doses of antibiotic can provide superior efficacy over other formulations with higher doses,” Kin F. Chan, PhD, executive vice president of research and development at BioPharmX Corporation, said in the release. “Usability studies indicate that BPX-01 distributes evenly, is not sticky and does not occlude or irritate the skin, indicating that it could offer a significant advancement in the treatment of acne.”

According to the release the American Academy of Dermatology, acne is the “most common skin condition in the United States,” affecting 40 to 50 million Americans at any given moment and can lead to permanent scarring, low self-esteem, depression and anxiety.

The dermatology seminar will be held in Newport Beach, California, Oct. 23-24.